Hoyoung Huh has joined Cytomx, a US-based biotechnology company backed by Roche Venture Fund, the corporate venturing unit of the Swiss-based pharmaceutical company.
Huh was previously executive chairman of BiPar Sciences, which was bought by Sanofi-aventis for $500m in 2009. Huh is also chairman of US-based pharmaceutical company Geron Corporation.
The company’s former chairman, Charles Homcy, from US-based venture capital firm Third Rock Ventures, will stay on CytomX board of directors
CytomX Therapeutics, a US-based biotechnology company, raised $30m in 2010 in its series B round from a consortium including Roche Venture Fund.
The round was led by Third Rock Ventures, which earlier in the month closed its second fund above target at $426m, and Switzerland-based drugs company Roche’s corporate venturing division.
CytomX, which develops antibodies, previously raised $5m in its series A from angels, according to news provider VentureWire.